Grant Details

GRANT OVERVIEW

Grant name and funding organization

NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)

National Institutes of Health (NIH)

Total funding amount and duration

Funding amount is not limited but must reflect the actual needs of the proposed project.

Maximum project period is 5 years.

Primary objective and mission statement

To support high-risk, multi-center clinical trials that are hypothesis-driven and focus on diseases relevant to the NIDDK mission.

Trials should have the potential to change clinical practice and/or public health.

Key stakeholders and beneficiaries

Investigators and research teams conducting clinical trials.

Patients and communities affected by diabetes, digestive, and kidney diseases.

ELIGIBILITY CRITERIA

Organization Requirements

Eligible organization types include higher education institutions, nonprofits, for-profit organizations, small businesses, local, state, and federal governments.

Non-domestic entities (foreign organizations) are not eligible to apply.

Geographic Scope

Applications must be from organizations based in the U.S.

Non-domestic components of U.S. organizations are not eligible.

Project Requirements

Projects must propose therapeutic clinical trials.

Planning activities must be completed prior to submission and are not permitted under this NOFO.

Financial Requirements

Application budgets are not limited but must reflect the actual needs of the proposed project.

Timeline Requirements

Applications are due by 5:00 PM local time of the applicant organization.

Key dates include application due dates and review cycles.

Previous Funding Considerations

The NIH will not accept duplicate or highly overlapping applications under review at the same time.

APPLICATION PROCESS

Required documentation and materials

Applications must include a detailed study protocol, budget, and letters of support from clinical centers.

Evaluation criteria and scoring system

Applications will be evaluated based on significance, innovation, rigor, and feasibility.

Review process and timeline

Applications will undergo peer review and be evaluated for scientific and technical merit.

Selection criteria and priorities

Applications that align with NIDDK's mission and priorities will be prioritized.

SPECIAL CONSIDERATIONS

Unique aspects or requirements

Engagement with community stakeholders is essential for the development and execution of the study.

Potential challenges or limitations

Non-responsive applications will not be reviewed and will be withdrawn from consideration.

Strategic alignment opportunities

Consultation with NIDDK staff is encouraged to ensure alignment with the institute's mission.

Competitive advantages or disadvantages

Strong community engagement and a well-defined study protocol can enhance competitiveness.

KEY INSIGHTS AND RECOMMENDATIONS

Critical success factors

Demonstrating substantial engagement with affected communities and stakeholders.

Common pitfalls to avoid

Submitting applications that do not comply with the specific instructions outlined in the NOFO.

Strategic recommendations for applicants

Engage with NIDDK staff early in the application process to clarify expectations and requirements.

Competitive positioning advice

Highlight the potential impact of the proposed trial on clinical practice and public health.

Grant Details

clinical trials healthcare public health diabetes digestive diseases kidney diseases multi-center studies therapeutic interventions research funding community engagement
NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
PA-25-147
NIDDK
EDU NGO PUBLIC ENTERPRISE SME OTHER
US
RESEARCH_DEVELOPMENT
False
None
None
None
USD
None
True
True
The funded projects are expected to improve understanding, diagnosis, prevention, or treatment of diseases relevant to the NIDDK mission.
Specific outputs include a detailed study protocol, engagement with community stakeholders, and a comprehensive data management plan.
Nov. 5, 2026, 10 p.m.
March 2025 - November 2026
Detailed study protocol, budget, letters of support from clinical centers.
True
Applications will be evaluated based on significance, innovation, rigor, and feasibility.
Applications must demonstrate innovative approaches to clinical trials.
Applications must provide evidence of feasibility based on preliminary data.
Applications must articulate the potential impact on clinical practice and public health.
True
True
Cooperative Agreement
Recipients must comply with NIH policies and submit regular progress reports.
Annual progress reports and financial statements are required.
Payments will be made based on the approved budget and project milestones.
All NIH awards are subject to the terms and conditions outlined in the NIH Grants Policy Statement.
Research must align with the mission of NIDDK.